

ARGININE REPRESSOR DEFICIENT STRAIN OF CORYNEFORM
BACTERIUM AND METHOD FOR PRODUCING L-ARGININE

Field of the Invention

5 The present invention relates to a coryneform
bacterium having an ability to produce L-arginine and a
method for producing L-arginine using the bacterium. L-
arginine is an industrially useful amino acid as an
ingredient of liver function promoting agents, amino
10 acid infusions, comprehensive amino acid pharmaceuticals
and so forth.

Description of the Related Art

 Conventional L-arginine production by
15 fermentation has been performed by utilizing wild-type
strains of coryneform bacteria; coryneform bacteria
resistant to certain agents including sulfa drugs, 2-
thiazolealanine, α -amino- β -hydroxyvaleric acid and the
like; coryneform bacteria exhibiting auxotrophy for L-
20 histidine, L-proline, L-threonine, L-isoleucine, L-
methionine, or L-tryptophan in addition to the
resistance to 2-thiazolealanine (Japanese Patent Laid-
open No. 54-44096); coryneform bacteria resistant to
ketomalonic acid, fluoromalonic acid, or
25 monofluoroacetic acid (Japanese Patent Laid-open No. 57-
18989); coryneform bacteria resistant to argininol
(Japanese Patent Laid-open No. 62-24075); coryneform

bacteria resistant to X-guanidine (X represents a derivative of fatty acid or aliphatic chain, Japanese Patent Laid-open No. 2-186995) or the like.

On the other hand, there have also been disclosed methods for producing L-arginine utilizing recombinant DNA techniques. That is, there has been disclosed a method for producing L-arginine by utilizing a microorganism belonging to the genus *Corynebacterium* or *Brevibacterium* which is made to harbor a recombinant DNA comprising a vector DNA and a DNA fragment containing genes for acetylornithine deacetylase, N-acetylglutamic acid- α -semialdehyde dehydrogenase, N-acetyl glutamokinase, and argininosuccinase derived from a microorganism belonging to the genus *Escherichia* (Japanese Patent Publication No. 5-23750).

Further, as for coryneform bacteria, it has been elucidated that synthesis of some enzymes of the L-arginine biosynthetic system is repressed by L-arginine. Furthermore, it was reported that, while some of enzymes of L-arginine biosynthetic system were repressed by L-arginine, the repression of these enzymes by L-arginine was canceled in mutant strains of coryneform bacteria showing improved L-arginine accumulation amounts (*Agric. Biol. Chem.*, 43(1), 105, 1979).

Meanwhile, as for *Escherichia coli*, a repressor of L-arginine biosynthetic system and a gene coding for the repressor were identified (*Proc. Natl. Acad. Sci. U.S.A.*

(1987), 84(19), 6697-701), and binding interactions of the repressor protein and various genes of L-arginine biosynthetic system were also investigated (*Proc. Natl. Acad. Sci. U.S.A.* (1987), 84(19), 6697-701, *J. Mol. Biol.* (1992), 226, 367-386).

However, any repressor proteins of the L-arginine biosynthetic system have not been identified in coryneform bacteria. While a nucleotide sequence of the repressor protein gene (*argR*) and an amino acid sequence assumed to be encoded thereby are registered in a gene database, GenBank (AF049897), the gene is considered to be designated *argR* because of the homology between the aforementioned amino acid sequence and known arginine repressors.

Summary of the Invention

As described above, although a repressor protein of the L-arginine biosynthetic system of coryneform bacteria and a gene thereof are expected, the repressor protein itself has not been identified and its functions and so forth are not elucidated at all. Therefore, an object of the present invention is to identify the repressor of the L-arginine biosynthesis in coryneform bacteria, and improve L-arginine productivity of coryneform bacteria.

The inventors of the present invention isolated a

homologue of the gene registered as *argR* in the gene database (GenBank accession AF049897) from a coryneform bacterium, and found that, if this gene was amplified in coryneform bacteria, L-arginine producing ability was decreased, and on the other hand, if the gene was disrupted, the L-arginine producing ability was improved, to confirm that the L-arginine biosynthesis is repressed by a repressor in coryneform bacteria like *Escherichia coli* and the aforementioned gene registered as *argR* codes for the repressor. Thus, the present invention was accomplished.

That is, the present invention provides the followings.

(1) A coryneform bacterium in which an arginine repressor does not function in a normal manner, and which has L-arginine producing ability.

(2) The coryneform bacterium according to (1), wherein the arginine repressor does not function in a normal manner due to disruption of a gene coding for the arginine repressor on a chromosome of the bacterium.

(3) The coryneform bacterium according to (2), wherein the arginine repressor has the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence showing homology to the amino acid sequence.

(4) A method for producing L-arginine, which comprises culturing a coryneform bacterium according to any one of (1) to (3) in a medium to produce and accumulate L-

arginine in the medium, and collecting the L-arginine from the medium.

In the present invention, the "arginine repressor" refers to a protein that has an effect of repressing the L-arginine biosynthesis, and if expression amount of the gene that codes for the protein increases in coryneform bacteria, L-arginine producing ability will be reduced, and if the expression amount decreases or the protein disappears, the L-arginine producing ability will be improved. Hereafter, the gene coding for the arginine repressor is also called *argR* gene. Further, the "L-arginine producing ability" used in the present invention refers to an ability of the microorganism of the present invention to accumulate L-arginine in a medium, when it is cultured in the medium.

According to the present invention, L-arginine producing ability of coryneform bacteria having the L-arginine producing ability can be improved.

Brief Explanation of the Drawings

Fig. 1 shows the construction process of plasmid pK1.

Fig. 2 shows the construction process of plasmid pSFK6.

Fig. 3 shows the construction process of plasmid pSFKT2.

Hereafter, the present invention will be explained in detail.

The microorganism of the present invention is a coryneform bacterium having L-arginine producing ability, in which arginine repressor does not function in a normal manner. The coryneform bacterium of the present invention may be a microorganism having the L-arginine producing ability because an arginine repressor does not function in a normal manner in it, or a microorganism bred so that the arginine repressor should not function in a normal manner in it. Alternatively, it may be a microorganism that is bred so that the arginine repressor should not function in a normal manner in it and then imparted with the L-arginine producing ability.

The coryneform bacteria include bacteria having been hitherto classified into the genus *Brevibacterium* but united into the genus *Corynebacterium* at present (*Int. J. Syst. Bacteriol.*, 41, 255 (1981)), and include bacteria belonging to the genus *Brevibacterium* closely relative to the genus *Corynebacterium*. Examples of such coryneform bacteria include the followings.

Corynebacterium acetoacidophilum

Corynebacterium acetoglutamicum

Corynebacterium alkanolyticum

Corynebacterium callunae

Corynebacterium glutamicum

Corynebacterium lilium (*Corynebacterium glutamicum*)

Corynebacterium melassecola

Corynebacterium thermoaminogenes

5 *Corynebacterium herculis*

Brevibacterium divaricatum

(*Corynebacterium glutamicum*)

Brevibacterium flavum (*Corynebacterium glutamicum*)

Brevibacterium immariophilum

10 *Brevibacterium lactofermentum*

(*Corynebacterium glutamicum*)

Brevibacterium roseum

Brevibacterium saccharolyticum

Brevibacterium thiogenitalis

15 *Brevibacterium album*

Brevibacterium cerinum

Microbacterium ammoniaphilum

While the coryneform bacteria that have the L-arginine-producing ability are not particularly limited so long as they have the L-arginine-producing ability, they include, for example, wild-type strains of coryneform bacteria; coryneform bacteria resistant to certain agents including sulfa drugs, 2-thiazolealanine, α -amino- β -hydroxyvaleric acid and the like; coryneform bacteria exhibiting auxotrophy for L-histidine, L-proline, L-threonine, L-isoleucine, L-methionine, or L-tryptophan in addition to the resistance to 2-

20

25

thiazolealanine (Japanese Patent Laid-open No. 54-44096); coryneform bacteria resistant to ketomalononic acid, fluoromalononic acid, or monofluoroacetic acid (Japanese Patent Laid-open No. 57-18989); coryneform bacteria resistant to argininol (Japanese Patent Laid-open No. 62-24075); coryneform bacteria resistant to X-guanidine (X represents a derivative of fatty acid or aliphatic chain, Japanese Patent Laid-open No. 2-186995) and the like.

Specifically, the following strains can be exemplified.

Brevibacterium flavum AJ11169 (BP-6892)

Corynebacterium glutamicum AJ12092 (FERM BP-6906)

Brevibacterium flavum AJ11336 (FERM BP-6893)

Brevibacterium flavum AJ11345 (FERM BP-6894)

Corynebacterium glutamicum AJ12430 (FERM BP-2228)

The AJ11169 strain and the AJ12092 strain are the 2-thiazolealanine resistant strains mentioned in Japanese Patent Laid-open No. 54-44096, the AJ11336 strain is the strain having argininol resistance and sulfadiazine resistance mentioned in Japanese Patent Publication No. 62-24075, the AJ11345 strain is the strain having argininol resistance, 2-thiazolealanine resistance, sulfaguanidine resistance, and exhibiting histidine auxotrophy mentioned in Japanese Patent Publication No. 62-24075, and the AJ12430 strain is the strain having octylguanidine resistance and 2-

thiazolealanine resistance mentioned in Japanese Patent Laid-open No. 2-186995.

AJ11169 was deposited on August 3, 1977 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently National Institute of Bioscience and Human Technology, National Institute of Advanced Industrial Science and Technology, Ministry of Economy, Trade and Industry)(zip code: 305-8566, 1-3 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan), as deposition number of FERM P-4161, and transferred from the original deposit to international deposit based on Budapest Treaty on September 27, 1999, and has been deposited as deposition number of FERM BP-6892.

AJ12092 was deposited on September 29, 1983 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, as deposition number of FERM P-7273, and transferred from the original deposit to international deposit based on Budapest Treaty on October 1, 1999, and has been deposited as deposition number of FERM BP-6906.

AJ11336 was deposited on April 25, 1979 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, as deposition number

of FERM P-4939, and transferred from the original deposit to international deposit based on Budapest Treaty on September 27, 1999, and has been deposited as deposition number of FERM BP-6893.

5 AJ11345 was deposited on April 25, 1979 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, as deposition number of FERM P-4948, and transferred from the original
10 deposit to international deposit based on Budapest Treaty on September 27, 1999, and has been deposited as deposition number of FERM BP-6894.

AJ12430 was deposited on December 26, 1988 in National Institute of Bioscience and Human Technology,
15 Agency of Industrial Science and Technology of Ministry, International Trade and Industry based on Budapest Treaty, as deposition number of FERM BP-2228.

The coryneform bacterium whose arginine repressor does not function in a normal manner can be obtained by
20 modifying its *argR* gene so that the activity of the arginine repressor should be reduced or eliminated, or the transcription of the *argR* gene should be reduced or eliminated. Such a coryneform bacterium can be obtained by, for example, replacing the chromosomal *argR* gene
25 with an *argR* gene that does not function in a normal manner (occasionally referred to as "disrupted *argR* gene" hereinafter) through, for example, homologous

recombination based on genetic recombination techniques (Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press (1972); Matsuyama, S. and Mizushima, S., *J. Bacteriol.*, 162, 1196 (1985)).

5 In the homologous recombination, when a plasmid carrying a sequence exhibiting homology with a chromosomal sequence or the like is introduced into a corresponding bacterial cell, recombination occurs at a site of the homologous sequence at a certain frequency, and thus the introduced plasmid as a whole is integrated
10 into the chromosome. Then, by causing recombination again at the site of the homologous sequence in the chromosome, the plasmid may be removed from the chromosome. However, depending on the position at which
15 the recombination is caused, the disrupted gene may remain on the chromosome, while the original normal gene may be removed from the chromosome together with the plasmid. By selecting such a bacterial strain, a bacterial strain in which the normal *argR* gene is
20 replaced with a disrupted *argR* gene can be obtained.

 Such a gene disruption technique based on the homologous recombination has already been established, and a method utilizing a linear DNA, method utilizing temperature sensitive plasmid or the like can be used
25 therefor. The *argR* gene can also be disrupted by using a plasmid that contains the *argR* gene inserted with a marker gene such as drug resistance gene, and cannot

replicate in a target cell of the coryneform bacterium. That is, in a transformant that has been transformed with such a plasmid and hence acquired drug resistance, the marker gene is integrated in a chromosome DNA. It is likely that this marker gene has been integrated by homologous recombination of the *argR* gene present at the both sides of the marker with the *argR* on the chromosome, and therefore a gene-disrupted strain can efficiently be selected.

Specifically, a disrupted *argR* gene used for the gene disruption can be obtained by deletion of a certain region of *argR* gene by means of digestion with restriction exzyme(s) and religation; by insertion of another DNA fragment (marker gene etc.) into the *argR* gene, by introducing substitution, deletion, insertion, addition or inversion of one or more nucleotides in a nucleotide sequence of coding region of *argR* gene, its promoter region or the like by means of site-specific mutagenesis (Kramer, W. and Frits, H. J., *Methods in Enzymology*, 154, 350 (1987)) or treatment with a chemical reagent such as sodium hyposulfite and hydroxylamine (Shortle, D. and Nathans, D., *Proc. Natl. Acad. Sci. U.S.A.*, 75, 270(1978)) or the like, so that the activity of the encoded repressor should be reduced or eliminated, or transcription of the *argR* gene should be reduced or eliminated. Among these embodiments, a method utilizing deletion of a certain region of the

argR gene by digestion with a restriction enzyme and religation, or insertion of another DNA fragment into the *argR* gene is preferred in view of reliability and stability.

5 A plasmid for the *argR* gene disruption can be produced by performing PCR (polymerase chain reaction) using a plasmid containing the *argR* gene and its flanking regions as a template and primers corresponding the terminal portions or flanking regions of the *argR*
10 gene to amplify a portion except for an internal portion or the whole portion of the *argR* gene, and cyclizing the obtained amplified product. In the examples mentioned hereinafter, the *argR* gene was disrupted by this method.

 The *argR* gene can be obtained from a chromosomal
15 DNA of a coryneform bacterium by PCR using oligonucleotides prepared based on known nucleotide sequences of the *argR* gene as primers. The *argR* gene can also be obtained from a chromosome DNA library of a microorganism which has a purine operon by a
20 hybridization technique using an oligonucleotide prepared based on a known nucleotide sequence of the *argR* gene as a probe. For the purpose of the present invention, because the *argR* gene is used for preparing a disrupted *argR* gene, it is not necessarily required to
25 contain the full length, and it may contain a length required to cause gene disruption.

 The origin of the *argR* gene is not particularly

limited, so long as it has such a degree of homology that it should cause homologous recombination with the *argR* gene of coryneform bacteria. Specifically, the *argR* gene of the *Brevibacterium flavum*, which has the nucleotide sequence shown in SEQ ID NO: 17, and the *argR* gene of *Corynebacterium glutamicum* (GenBank accession AF049897) can be mentioned as the *argR* genes of coryneform bacteria. These *argR* genes are highly homologous, and it is considered that even an *argR* gene of coryneform bacterium of a genus or species different from that of a coryneform bacterium of which *argR* gene is to be disrupted may also be used for the gene disruption.

In the present invention, the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence exhibiting homology to the amino acid sequence means an amino acid sequence that is encoded by an *argR* gene having such a degree of homology that it should cause homologous recombination with the *argR* gene coding to the amino acid sequence shown in SEQ ID NO: 18 (for example, an *argR* gene having the nucleotide sequence shown in SEQ ID NO: 17).

As the primers used for PCR, any primers that allow amplification of the *argR* gene can be used. Specific examples thereof include the oligonucleotides having the nucleotide sequences shown in SEQ ID NOS: 19 and 20.

Further, examples of marker gene include drug resistance genes such as a kanamycin resistance gene. A kanamycin resistance gene can be obtained by PCR amplification from a known plasmid containing a

5 kanamycin resistance gene of *Streptococcus faecalis*, for example, pDG783 (Anne-Marie Guerout-Fleury et al., *Gene*, 167, 335-337 (1995)).

When a drug resistance gene is used as the marker gene, an *argR* gene-disrupted strain can be obtained by

10 inserting the drug resistance gene into a suitable site of the *argR* gene carried by a plasmid, transforming a microorganism with the plasmid, and selecting a drug resistant transformant. Disruption of *argR* gene on a chromosome can be confirmed by analyzing the *argR* gene

15 or the marker gene on the chromosome by Southern blotting, PCR, or the like. Integration of the kanamycin resistance gene into a chromosomal DNA can be confirmed by PCR using primers that allow amplification of the kanamycin resistance gene (e.g., oligonucleotides

20 having nucleotide sequences shown in SEQ ID NOS: 1 and 2).

L-arginine can be efficiently produced by culturing a coryneform bacterium having L-arginine producing ability obtained as described above, in which

25 an arginine repressor does not function in a normal manner, in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the

medium.

The medium to be used may be selected from well-known media conventionally used for fermentative production of amino acids utilizing microorganisms.

5 That is, it may be a usual medium that contains a carbon source, nitrogen source, inorganic ions, and other organic ingredients as required.

As the carbon source, there can be used saccharides such as glucose, sucrose, lactose, galactose,
10 fructose or starch hydrolysate, alcohols such as glycerol or sorbitol, or organic acids such as fumaric acid, citric acid or succinic acid.

As the nitrogen source, there can be used inorganic ammonium salts such as ammonium sulfate,
15 ammonium chloride or ammonium phosphate, organic nitrogen such as soybean protein hydrolysate, ammonia gas, aqueous ammonia and so forth.

It is desirable to add required substances such as vitamin B₁ and L-homoserine, yeast extract and so forth
20 to the medium in appropriate amounts as organic trace nutrients. Other than the above, potassium phosphate, magnesium sulfate, iron ion, manganese ion and so forth are added in small amounts as required.

The culture is preferably carried out under an
25 aerobic condition for 1-7 days. The culture temperature is preferably controlled to be 24°C to 37°C, and pH is preferably controlled to be 5-9 during the culture.

Inorganic or organic, acidic, alkaline substances, or ammonia gas and so forth can be used for pH adjustment. L-arginine can be collected from the fermentation broth usually by a combination of well-known techniques such as ion exchange resin techniques and other techniques.

Best Mode for Carrying out the Invention

Hereafter, the present invention will be explained more specifically with reference to the following examples.

Example 1: Constructions of shuttle vector for *Escherichia coli* and coryneform bacteria and temperature sensitive vector

First, a vector for introducing an *argR* gene into coryneform bacteria and a temperature sensitive vector for producing an *argR* deficient strain of coryneform bacterium were constructed.

<1> Construction of vector having drug resistance gene of *Streptococcus faecalis*

The kanamycin resistance gene of *Streptococcus faecalis* was amplified by PCR from a known plasmid containing the gene. The nucleotide sequence of the kanamycin resistance gene of *Streptococcus faecalis* has

already been elucidated (Trieu-Cuot, P. and Courvalin, P.: *Gene*, 23 (3), 331-341 (1983)). Based on this sequence, the primers shown in SEQ ID NOS: 1 and 2 were synthesized, and PCR was performed by using pDG783 (Anne-Marie Guerout-Fleury, et al., *Gene*, 167, 335-337 (1995)) as a template to amplify a DNA fragment containing the kanamycin resistance gene and its promoter.

The aforementioned DNA fragment was purified by using SUPREC02 produced by Takara Shuzo Co., Ltd., and then completely digested with restriction enzymes *HindIII* and *HincII* to be blunt-ended. The blunt-ending was performed by using Blunting Kit produced by Takara Shuzo Co., Ltd. This DNA fragment was mixed with a DNA fragment obtained by purification and blunt-ending of an amplification product of PCR performed by using the primers shown in SEQ ID NOS: 3 and 4 and pHSG399 (see S. Takeshita, et al.: *Gene*, 61, 63-74 (1987)) as a template, and ligated both fragments. The ligation was performed by using DNA Ligation Kit Ver. 2 produced by Takara Shuzo Co., Ltd. Competent cells of *Escherichia coli* JM109 (produced by Takara Shuzo Co., Ltd.) were transformed with the ligated DNA, plated on L medium (10 g/L of Bacto trypton, 5 g/L of Bacto yeast extract, 5 g/L of NaCl, 15 g/L of agar, pH 7.2) containing 10 µg/ml of IPTG (isopropyl-β-D-thiogalactopyranoside), 40 µg/ml of X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside)

and 25 µg/ml of kanamycin, and cultured overnight. The emerged blue colonies were picked up, and separated into single colonies to obtain transformant strains.

Plasmids were prepared from the transformant strains by the alkali method (Seibutsu Kogaku Jikkensyo (Text for Bioengineering Experiments), Edited by the Society for Bioscience and Bioengineering, Japan, p.105, Baifukan, 1992), and restriction maps were prepared. One having a restriction map equivalent to that of Fig. 1 was designated as pK1. This plasmid is stably harbored in *Escherichia coli*, and imparts kanamycin resistance to a host. Moreover, since it contains the lacZ' gene, it is suitably used as a cloning vector.

15 <2> Construction of shuttle vector pSFK6

As a material for obtaining a temperature sensitive replication control region, a plasmid vector autonomously replicable in both of *Escherichia coli* cells and coryneform bacteria cells was prepared. The plasmid pAM330 extracted from *Brevibacterium lactofermentum* ATCC13869 [see Japanese Patent Publication Laid-open (Kokai) No. 58-67699] was completely digested with a restriction enzyme *HindIII*, and blunt-ended. This fragment was ligated to a fragment obtained by completely digesting the aforementioned pK1 with a restriction enzyme *BsaAI*. *Brevibacterium lactofermentum* ATCC13869 was transformed

with the ligated DNA. The transformation was performed by the electric pulse method [see Japanese Patent Publication Laid-open (Kokai) No. 2-207791].

Transformants were selected on an M-CM2B plate (10 g/L of polypeptone, 10 g/L of yeast extract, 5 g/L of NaCl, 10 μ g/L of biotin, 15 g/L of agar, pH 7.2) containing 25 μ g/ml of kanamycin. After cultivation for 2 days, colonies were picked up, and separated into single colonies to obtain the transformants. Plasmid DNAs were prepared from the transformants, and restriction maps were prepared. One having the same restriction map as that of Fig. 2 was designated as pSFK6. This plasmid is autonomously replicable in both of *Escherichia coli* and coryneform bacteria, and imparts kanamycin resistance to a host.

<3> Construction of a plasmid having temperature sensitive replication control region

pSFK6 was treated with hydroxylamine *in vitro*.

The hydroxylamine treatment was performed according to a known method [see, for example, G.O. Humpherys, *et al.*, *Molec. Gen. Genet.*, 145, 101-108 (1976)]. DNA undergone the treatment was collected and used for transformation of *Brevibacterium lactofermentum* ATCC13869 strain. The transformants were selected at a low temperature (25°C) on a CM2B plate containing 25 μ g/ml of kanamycin. The appeared transformants were replicated to a similar

selection plate, and cultured at an elevated temperature (34°C). One strain that could not grow on the selection plate containing kanamycin at the elevated temperature was obtained. From this strain, a plasmid was recovered and designated as p48K.

<4> Determination of nucleotide sequence of temperature sensitive replication control region

Nucleotide sequences of replication control region segments in the plasmid pSFK6 having a wild-type replication control region and the plasmid p48K having a temperature sensitive replication control region were determined. The nucleotide sequences were determined on a fully automatic sequencer, ABI310 (ABI), by using DNA Sequencing Kit from ABI. As a result, it was found that there were 6 nucleotide substitutions between the wild-type replication control region and the temperature sensitive replication control region. The nucleotide sequence of the temperature sensitive replication control region segment contained in pSFK6 (derived from full sequence of pAM330), which functions in coryneform bacteria, is shown in SEQ ID NO: 5, and the nucleotide sequence of the temperature sensitive replication control region segment contained in p48K, which functions in coryneform bacteria, is shown in SEQ ID NO: 7. Further, the amino acid sequences encoded by ORFs contained in these nucleotide sequences are shown in SEQ

ID NOS: 6 and 8. In the temperature sensitive replication control region, the 1255th C is mutated to T, the 1534th C to T, the 1866th G to A, the 2058th G to A, the 2187th C to T and 3193rd G to A. Among these, only
 5 the mutation at 1534th position is accompanied by an amino acid mutation, and causes substitution of serine for proline.

10 <5> Construction of shuttle vectors having temperature sensitive mutation

Each one of the six mutations of p48K was introduced into a shuttle vector pSFK6 (see Fig. 3). The introduction of the mutations was performed by a known method [Mikaelian, I., Sergeant, A., *Nucleic Acids Res.*, 20, 376 (1992)]. Specific procedure will be
 15 mentioned below. In order to introduce the mutation of 1534th C to T, PCR was performed by using a combination of the primers shown in SEQ ID NOS: 9 and 10 (primers 9 and 10), and a combination of the primers shown in SEQ
 20 ID NOS: 11 and 12 (primers 11 and 12), and pAM330 as a template. Each of the obtained amplification products was purified by subjecting them to agarose gel electrophoresis, and collecting them from the gel. The collection of the DNA fragments from the gel was
 25 performed by using EASYTRAP Ver.2 (Takara Shuzo Co., Ltd.). The purified DNAs were mixed in a molar ratio of 1:1, and used as a template for PCR performed by using

the primers shown SEQ ID NOS: 13 and 14 (primers 13 and 14). The amplification product was fully digested with a restriction enzyme MluI, and subjected to agarose gel electrophoresis to recover a DNA fragment of about 3.2 kb. Similarly, pSFK6 was also completely digested with a restriction enzyme MluI, and subjected to agarose gel electrophoresis to recover a DNA fragment of about 3.8 kb. The obtained DNA fragments were mixed and ligated, and used to transform competent cells of *Escherichia coli* JM109 (Takara Shuzo Co., Ltd.). The cells were applied on L medium containing 25 µg/ml of kanamycin, and cultured overnight. The appeared colonies were picked up, and isolated single colonies to obtain transformant strains. A plasmid was prepared from the transformant strains by the alkaline method, and the nucleotide sequence of the plasmid was determined to confirm that 1534th C in the sequence shown in SEQ ID NO: 5 was mutated to T. This plasmid was designated as pSFKT2 (Fig. 3).

20

Example 2: Cloning of *argR* gene and amplification effect thereof in coryneform bacteria

PCR was performed by using chromosome DNA of the *Brevibacterium flavum* wild strain 2247 (AJ14067) as a template and the oligonucleotides having the nucleotide sequences shown in SEQ ID NO: 15 (sequence of the

25

nucleotide numbers 1717-1741 in SEQ ID NO: 17) and SEQ ID NO: 16 (sequence complementary to the sequence of the nucleotide numbers 2386-2362 in SEQ ID NO: 17) as primers (Primers 15 and 16). PCR was performed for 30 cycles with each cycle consisting of reactions at 98°C for 10 seconds, 58°C for 1 minute and 72°C for 3 minutes by using Pyrobest DNA polymerase (Takara Shuzo Co., Ltd.). The obtained amplified fragment was inserted into the *Sma*I site of the shuttle vector pSFK6 obtained in Example 1 to obtain plasmid pWR autonomously replicable in coryneform bacteria.

In order to investigate the amplification effect of *argR* gene in L-arginine producing coryneform bacteria, pWR was introduced into the AJ113455 strain (FERM BP-6894), which is an L-arginine producer of *Brevibacterium flavum*. The plasmid was introduced by the electric pulse method (Japanese Patent Laid-open No. 2-207791). A transformant was selected as a kanamycin resistant strain on CM2G agar medium (containing 5 g of glucose, 5 g of NaCl and 15 g of agar in 1 L of pure water, pH 7.2) containing 25 µg/ml of kanamycin to obtain AJ11345/pWR. As a control, pSFK6 was similarly introduced into the AJ113455 strain to obtain a transformant AJ11345/pSFK6.

Each of the aforementioned strains was plated on an agar medium containing 0.5 g/dl of glucose, 1 g/dl of polypeptone, 1 g/dl of yeast extract and 0.5 g/dl of NaCl, and cultured at 31.5°C for 20 hours. One platinumum

loop of the obtained cells were inoculated into a medium containing 4 g/dl of glucose, 6.5 g/dl of ammonium sulfate, 0.1 g/dl of KH_2PO_4 , 0.04 g/dl of MgSO_4 , 0.001 g/dl of FeSO_4 , 0.001 g/dl of MnSO_4 , 5 $\mu\text{g/dl}$ of vitamin B_1 , 5 $\mu\text{g/dl}$ of biotin and soybean protein hydrolysate (45 mg/dl as N amount), and cultured in a flask at 31.5°C for 50 hours with shaking. Accumulation amount of L-arginine (concentration, g/dl) in each culture broth was measured. The results are shown in Table 1. As a result, the *argR*-amplified strain hardly accumulated L-arginine. This demonstrated that the *argR* gene product functioned as an arginine repressor.

Table 1

Strain	L-Arginine accumulation amount (g/dl)
AJ11345/pSFK6	1.3
AJ11345/pWR	0.2

The result of nucleotide sequencing for the inserted fragment cloned in pWR is shown in SEQ ID NO: 17. An amino acid sequence that may be encoded by that nucleotide sequence is shown in SEQ ID NO: 18.

Example 3: Construction of *argR*-disrupted strain of coryneform bacterium and effect of deletion of arginine repressor

<1> Construction of plasmid for *argR* disruption

PCR was performed by using chromosome DNA of a

wild strain of *Brevibacterium flavum*, 2247 strain (AJ14067), as a template and the oligonucleotides having the nucleotide sequences shown in SEQ ID NO: 19 (sequence of the nucleotide numbers 4-28 in SEQ ID NO: 17) and SEQ ID NO: 20 (sequence complementary to the sequence of the nucleotide numbers 4230-4211 in SEQ ID NO: 17) as primers (Primers 19 and 20). PCR was performed for 30 cycles with each cycle consisting of reactions at 98°C for 10 seconds, 58°C for 1 minute and 72°C for 3 minutes by using Pyrobest DNA polymerase (Takara Shuzo Co., Ltd.). The obtained amplified fragment was inserted into the *Sma*I site in a multicloning site of cloning vector pHSG399.

In order to delete the whole ORF considered to encode the arginine repressor from the inserted DNA fragment, PCR was performed by using the oligonucleotides having the nucleotide sequences shown in SEQ ID NO: 21 (sequence of the nucleotide numbers 2372-2395 in SEQ ID NO: 17) and SEQ ID NO: 22 (sequence complementary to the sequence of the nucleotide numbers 1851-1827 in SEQ ID NO: 17) as primers (Primers 21 and 22) and pHSG399 inserted with the amplified fragment as a template. pssER was constructed by self-ligation of the PCR product.

Then, a fragment obtained by digesting pssER with restriction enzymes *Sma*I and *Sal*I and the temperature sensitive plasmid pSFKT2 obtained in Example 1 and

digested with *Sma*I and *Sal*I were ligated to obtain plasmid pssERT for *argR* disruption whose autonomous replication ability in coryneform bacteria became temperature sensitive.

5

<2> Construction of arginine repressor deficient strain of coryneform bacterium by homologous recombination

The plasmid pssERT obtained as described above was introduced into the *Brevibacterium lactofermentum* AJ13029 strain (FERM BP-5189). The plasmid was introduced by the electric pulse method (Japanese Patent Laid-open No. 2-207791). Because autonomous replication ability of this plasmid is temperature sensitive in *Brevibacterium lactofermentum*, only strains in which this plasmid was incorporated into the chromosome by homologous recombination could be selected as kanamycin resistant strains at 34°C, which was a temperature that did not allow replication of the plasmid. Strains in which the plasmid for *argR* disruption was incorporated into a chromosome were selected as kanamycin resistant strains on a CM2G plate (containing 10 g/L of polypeptone, 10 g/L of yeast extract, 5 g/L of glucose, 5 g/L of NaCl and 15 g/L of agar in 1 L of water, pH 7.2) containing 25 µg/ml of kanamycin. At this stage, the normal *argR* gene derived from the chromosome and the *argR* gene derived from the plasmid in which OFR was deleted were present in tandem at the both sides of the

plasmid portion on the chromosome.

Then, the recombinant strains were allowed to cause homologous recombination again, and strains that became kanamycin sensitive at 34°C, which was a temperature that did not allow the plasmid replication, were selected as strains in which one of the *argR* genes was deleted. These strains include strains in which the normal *argR* gene remained on the chromosome and strains in which the disrupted *argR* gene remained on the chromosome. From these strains, a strain having only the disrupted *argR* gene was selected. An *argR* gene on the chromosome is determined to be the disrupted type by preparing chromosome of a strain that became kanamycin sensitive at 34°C, performing PCR utilizing the chromosome as a template and the oligonucleotides having the nucleotide sequences shown in SEQ ID NOS: 19 and 20 as primers (Primers 19 and 20), and confirming that the PCR product was shorter by about 600 bp than that obtained by similarly performing PCR utilizing chromosome derived from the parent strain as a template.

Direct sequencing of the PCR product of the *argR*-disrupted strain selected as described above was performed to confirm that the *argR* gene was disrupted as desired, and thus AJ13029ΔR stain was obtained.

25

<3> Production of L-arginine with *argR*-disrupted strain

The AJ13029ΔR strain was plated on an agar medium

containing 0.5 g/dl of glucose, 1 g/dl of polypeptone, 1 g/dl of yeast extract and 0.5 g/dl of NaCl, and cultured at 31.5°C for 20 hours. One platinum loop of the obtained cells were inoculated into a medium containing
5 3 g/dl of glucose, 6.5 g/dl of ammonium sulfate, 0.1 g/dl of KH_2PO_4 , 0.04 g/dl of MgSO_4 , 0.001 g/dl of FeSO_4 , 0.001 g/dl of MnSO_4 , 300 $\mu\text{g/dl}$ of vitamin B_1 , 200 $\mu\text{g/dl}$ of biotin and soybean protein hydrolysate (165 mg/dl as N amount) and adjusted to pH 7.0 with NaOH, and cultured
10 at 31.5°C for 24 hours as seed culture.

The above seed culture broth was inoculated in an amount of 1 ml into a medium containing 4 g/dl of glucose, 6.5 g/dl of ammonium sulfate, 0.5 g/dl of KH_2PO_4 , 0.04 g/dl of MgSO_4 , 0.001 g/dl of FeSO_4 , 0.01
15 g/dl of MnSO_4 , 5 $\mu\text{g/dl}$ of vitamin B_1 , 5 $\mu\text{g/dl}$ of biotin and soybean protein hydrolysate (45 mg/dl as N amount) and adjusted to pH 7.0 with KOH, and cultured in a flask at 31.5°C for 50 hours with shaking. Accumulation amount of L-arginine (concentration, mg/dl) in culture
20 broth of each strain was measured. The results are shown in Table 2. As a result, the *argR*-disrupted strain accumulated L-arginine in a markedly larger amount compared with the parent strain.

Table 2

Strain	L-Arginine accumulation amount (mg/dl)
AJ13029	20
AJ13029 Δ R	120

(Explanation of Sequence Listing)

- 5 SEQ ID NO: 1: primer for amplification of kanamycin
resistance gene of *Streptococcus faecalis*
- SEQ ID NO: 2: primer for amplification of kanamycin
resistance gene of *Streptococcus faecalis*
- 10 SEQ ID NO: 3: primer for amplification of vector portion
of pHSG399
- SEQ ID NO: 4: primer for amplification of vector portion
of pHSG399
- SEQ ID NO: 5: nucleotide sequence of replication control
region of pSFK6
- 15 SEQ ID NO: 6: amino acid sequence that may be encoded by
ORF in pSFK6
- SEQ ID NO: 7: nucleotide sequence of replication control
region of p48K
- SEQ ID NO: 8: amino acid sequence that may be encoded by
- 20 ORF in p48K
- SEQ ID NO: 9: primer for 1st PCR for introducing
mutation of 1534th C to T into pSFK6
- SEQ ID NO: 10: primer for 1st PCR for introducing
mutation of 1534th C to T into pSFK6

- SEQ ID NO: 11: primer for 1st PCR for introducing mutation of 1534th C to T into pSFK6
- SEQ ID NO: 12: primer for 1st PCR for introducing mutation of 1534th C to T into pSFK6
- 5 SEQ ID NO: 13: primer for 2nd PCR for introducing mutation of 1534th C to T into pSFK6
- SEQ ID NO: 14: primer for 2nd PCR for introducing mutation of 1534th C to T into pSFK6
- SEQ ID NO: 15: primer for *argR* gene amplification
- 10 SEQ ID NO: 16: primer for *argR* gene amplification
- SEQ ID NO: 17: nucleotide sequence of DNA fragment containing *argR* gene
- SEQ ID NO: 18: amino acid sequence that may be encoded by the above DNA fragment
- 15 SEQ ID NO: 19: primer for *argR* gene amplification
- SEQ ID NO: 20: primer for *argR* gene amplification
- SEQ ID NO: 21: primer for amplifying portions other than *argR* gene ORF of plasmid containing *argR* gene
- SEQ ID NO: 22: primer for amplifying portions other than
- 20 *argR* gene ORF of plasmid containing *argR* gene

SEQUENCE LISTING

- <110> SUGA, Mikiko
 ASAKURA, Yoko
 MORI, Yukiko
 ITO, Hisao
 KURAHASHI, Osamu
- <120> Arginine Repressor Deficient Strain of Coryneform Bacterium and
 Method for Producing L-Arginine
- <130> OP1018
- <140>
 <141> 2001-04-
- <150> JP2000-129167
 <151> 2000-04-28
- <160> 22
- <170> PatentIn Ver. 2.0
- <210> 1
 <211> 32
 <212> DNA
 <213> Artificial Sequence
- <220>
 <223> Description of Artificial Sequence:primer for
 amplifying kanamycin resistant gene of
 Streptococcus faecalis
- <400> 1
 cccgttaact gcttgaaacc caggacaata ac

<210> 2

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for
amplifying kanamycin resistant gene of
Streptococcus faecalis

<400> 2

cccgttaaca tgtacttcag aaaagattag

30

<210> 3

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for
amplifying *Escherichia coli* cloning vector pHSG399

<400> 3

gatatctacg tgccgatcaa cgtctc

26

<210> 4

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for
amplifying *Escherichia coli* cloning vector pHSG399

<400> 4

aggccttttt ttaaggcagt tattg

25

<210> 5

<211> 4447

<212> DNA

<213> *Brevibacterium lactofermentum*

<220>

<221> CDS

<222> (1318)..(2598)

<400> 5

```

aagcttgtct acgtctgatg ctttgaatcg gacggacttg cegatcttgt atgcggtgat 60
ttttccctcg tttgccact ttttaatggt ggccggggtg agagctacgc gggcggcgac 120
ctgctgcgct gtgatccaat attcggggtc gttcactggt tcccccttct gattttctggc 180
atagaagaac ccccgatgaac tgtgtggttc cggggggttc tgatttttgc gagacttctc 240
gcgcaattcc ctagcttagg tgaaaacacc atgaaacact agggaaacac ccatgaaaca 300
cccattaggg cagtagggcg gcttcttcgt ctagggcttg catttgggcg gtgatctggt 360
cttttagcgtg tgaaagtgtg tcgtaggtgg cgtgctcaat gcactcgaac gtcacgtcat 420
ttaccgggtc acggtgggca aagagaacta gtgggttaga cattgttttc ctcgttgcg 480
gtgggtggtga gcttttctag ccgctcggta aacgcggcga tcatgaactc ttggaggttt 540
tcaccgttct gcatgcctgc gcgcttcag tcctcacgta gtgccaaagg aacgcgtgcg 600
gtgaccacga cgggcttagc ctttgctgc gcttctagtg cttcgatggt ggcttgtgcc 660
tgcgcttgct gcgcctgtag tgccgttga gcttcttgta gttgctgttc tagctgtgcc 720
ttggttgcca tgctttaaga ctctagtagc tttcctgcga tatgtcatgc gcatgcgtag 780
caaacattgt cctgcaactc attcattatg tgcagtgtc ctgttactag tcgtacatac 840
tcatatttac ctagtctgca tgcagtgcag gcacatgcag tcatgtcgtg ctaatgtgta 900
aaacatgtac atgcagattg ctgggggtgc agggggcgga gccaccctgt ccatgcgggg 960
tgtggggctt gccccgccg tacagacagt gagcacggg gcacctagtc gcgataccc 1020
cccctaggtg tcggacacgt aaccctccca tgcgatgca aatctttaac attgagtagc 1080
ggtaaactgg cagcatagc caagctaggc ggccaccaa caccactaaa aattaatagt 1140
ccctagacaa gacaaacccc cgtgcgagct accaactcat atgcacggg gccacataac 1200
ccgaagggtt ttcaattgac aaccatagca ctagctaaga caacgggcac aacaccgca 1260
caaactcgca ctgcgcaacc ccgcacaaca tcgggtctag gtaacactga aatagaa 1317
gtg aac acc tct aag gaa ccg cag gtc aat gag ggt tct aag gtc act 1365
Val Asn Thr Ser Lys Glu Pro Gln Val Asn Glu Gly Ser Lys Val Thr
      1           5           10           15
cgc gct agg gcg tgg cgt agg caa aac gtc atg tac aag atc acc aat 1413
Arg Ala Arg Ala Trp Arg Arg Gln Asn Val Met Tyr Lys Ile Thr Asn
      20           25           30
agt aag gct ctg gcg ggg tgc cat agg tgg cgc agg gac gaa gct gtt 1461
Ser Lys Ala Leu Ala Gly Cys His Arg Trp Arg Arg Asp Glu Ala Val
      35           40           45
gcg gtg tcc tgg tgc tct aac ggt gct tgc cag ttt gag ggt ctg caa 1509
Ala Val Ser Trp Ser Ser Asn Gly Ala Ser Gln Phe Glu Gly Leu Gln
      50           55           60
aac tct cac tct cgc tgg ggg tca cct ctg gct gaa ttg gaa gtc atg 1557

```

Asn	Ser	His	Ser	Arg	Trp	Gly	Ser	Pro	Leu	Ala	Glu	Leu	Glu	Val	Met	
65					70					75					80	
ggc	gaa	cgc	cgc	att	gag	ctg	gct	att	gct	act	aag	aat	cac	ttg	gcg	1605
Gly	Glu	Arg	Arg	Ile	Glu	Leu	Ala	Ile	Ala	Thr	Lys	Asn	His	Leu	Ala	
				85					90					95		
gcg	ggt	ggc	gcg	ctc	atg	atg	ttt	gtg	ggc	act	gtt	cga	cac	aac	cgc	1653
Ala	Gly	Gly	Ala	Leu	Met	Met	Phe	Val	Gly	Thr	Val	Arg	His	Asn	Arg	
			100					105				110				
tca	cag	tca	ttt	gcg	cag	gtt	gaa	gcg	ggt	att	aag	act	gcg	tac	tct	1701
Ser	Gln	Ser	Phe	Ala	Gln	Val	Glu	Ala	Gly	Ile	Lys	Thr	Ala	Tyr	Ser	
		115					120				125					
tcg	atg	gtg	aaa	aca	tct	cag	tgg	aag	aaa	gaa	cgt	gca	cgg	tac	ggg	1749
Ser	Met	Val	Lys	Thr	Ser	Gln	Trp	Lys	Lys	Glu	Arg	Ala	Arg	Tyr	Gly	
	130					135			140							
gtg	gag	cac	acc	tat	agt	gac	tat	gag	gtc	aca	gac	tct	tgg	gcg	aac	1797
Val	Glu	His	Thr	Tyr	Ser	Asp	Tyr	Glu	Val	Thr	Asp	Ser	Trp	Ala	Asn	
145					150			155								
ggt	tgg	cac	ttg	cac	cgc	aac	atg	ctg	ttg	ttc	ttg	gat	cgt	cca	ctg	1845
Gly	Trp	His	Leu	His	Arg	Asn	Met	Leu	Leu	Phe	Leu	Asp	Arg	Pro	Leu	
			165					170				175				
tct	gac	gat	gaa	ctc	aag	gcg	ttt	gag	gat	tcc	atg	ttt	tcc	cgc	tgg	1893
Ser	Asp	Asp	Glu	Leu	Lys	Ala	Phe	Glu	Asp	Ser	Met	Phe	Ser	Arg	Trp	
		180				185				190						
tct	gct	ggt	gtg	gtt	aag	gcc	ggt	atg	gac	gcg	cca	ctg	cgt	gag	cac	1941
Ser	Ala	Gly	Val	Val	Lys	Ala	Gly	Met	Asp	Ala	Pro	Leu	Arg	Glu	His	
	195				200			205								
ggg	gtc	aaa	ctt	gat	cag	gtg	tct	acc	tgg	ggt	gga	gac	gct	gcg	aaa	1989
Gly	Val	Lys	Leu	Asp	Gln	Val	Ser	Thr	Trp	Gly	Gly	Asp	Ala	Ala	Lys	
	210				215			220								
atg	gca	acc	tac	ctc	gct	aag	ggc	atg	tct	cag	gaa	ctg	act	ggc	tcc	2037
Met	Ala	Thr	Tyr	Leu	Ala	Lys	Gly	Met	Ser	Gln	Glu	Leu	Thr	Gly	Ser	
225					230			235								
gct	act	aaa	acc	gcg	tct	aag	ggg	tcg	tac	acg	cog	ttt	cag	atg	ttg	2085
Ala	Thr	Lys	Thr	Ala	Ser	Lys	Gly	Ser	Tyr	Thr	Pro	Phe	Gln	Met	Leu	
			245					250				255				
gat	atg	ttg	gcc	gat	caa	agc	gac	gcc	ggc	gag	gat	atg	gac	gct	gtt	2133
Asp	Met	Leu	Ala	Asp	Gln	Ser	Asp	Ala	Gly	Glu	Asp	Met	Asp	Ala	Val	
		260				265				270						
ttg	gtg	gct	cgg	tgg	cgt	gag	tat	gag	gtt	ggt	tct	aaa	aac	ctg	cgt	2181
Leu	Val	Ala	Arg	Trp	Arg	Glu	Tyr	Glu								

tcg tcc tgg tca cgt ggg gct aag cgt gct ttg ggc att gat tac ata 2229
 Ser Ser Trp Ser Arg Gly Ala Lys Arg Ala Leu Gly Ile Asp Tyr Ile
 290 295 300
 gac gct gat gta cgt cgt gaa atg gaa gaa gaa ctg tac aag ctc gcc 2277
 Asp Ala Asp Val Arg Arg Glu Met Glu Glu Glu Leu Tyr Lys Leu Ala
 305 310 315 320
 ggt ctg gaa gca ccg gaa cgg gtc gaa tca acc cgc gtt gct gtt gct 2325
 Gly Leu Glu Ala Pro Glu Arg Val Glu Ser Thr Arg Val Ala Val Ala
 325 330 335
 ttg gtg aag ccc gat gat tgg aaa ctg att cag tct gat ttc gcg gtt 2373
 Leu Val Lys Pro Asp Asp Trp Lys Leu Ile Gln Ser Asp Phe Ala Val
 340 345 350
 agg cag tac gtt cta gat tgc gtg gat aag gct aag gac gtg gcc gct 2421
 Arg Gln Tyr Val Leu Asp Cys Val Asp Lys Ala Lys Asp Val Ala Ala
 355 360 365
 gcg caa cgt gtc gct aat gag gtg ctg gca agt ctg ggt gtg gat tcc 2469
 Ala Gln Arg Val Ala Asn Glu Val Leu Ala Ser Leu Gly Val Asp Ser
 370 375 380
 acc cgc tgc atg atc gtt atg gat gat gtg gac ttg gac gcg gtt ctg 2517
 Thr Pro Cys Met Ile Val Met Asp Asp Val Asp Leu Asp Ala Val Leu
 385 390 395 400
 cct act cat ggg gac gct act aag cgt gat ctg aat gcg gcg gtg ttc 2565
 Pro Thr His Gly Asp Ala Thr Lys Arg Asp Leu Asn Ala Ala Val Phe
 405 410 415
 gcg ggt aat gag cag act att ctt cgc acc cac taaaagcggc ataaaccccg 2618
 Ala Gly Asn Glu Gln Thr Ile Leu Arg Thr His
 420 425
 ttgatattt tgtcgatga atttatggc aatgtcgcgg gggcaaaacta tgatgggtct 2678
 tgttgttgac aatggctgat ttcacagga atggaactgt catgctgtta tgtgcctggc 2738
 tcctaatcaa agctggggac aatgggttgc cccgttgatc tgatctagtt cggattggcg 2798
 gggcttcact gtatctgggg gtggcatcgt gaatagattg cacaccgtag tgggcagtgt 2858
 gcacaccata gtgggcatga gtaataccta cgcgcgcgtg ggctagggtc taacgcgcgt 2918
 ttgcccgtgc tgcggggcat acgtagcgc atacgctttt ttctgtgaaa cttttttgtg 2978
 ttgttgtttc gtgttggttt cttttctgtt ggcggggcaa cttaacgcct gcgggggttg 3038
 ttgttgacgt taacgggggt agtttttatt cccctagtgg tttttcagta cgacaatcga 3098
 gaaagacctg tttcagccag ttcgggtcat gttcgtcgtg atggccacgt gcatagcgac 3158
 cagttttcga gttcactggg attttttggt catcgaacaa gatgtaggac aatgcggttt 3218
 ctaggtctac tttttgcttt atgccgtaca agccccgtgg gtattcagcg attgattoca 3278
 aggcggcttc ccagtcctgt tttgtgaagg actggcctag ttctaggtct gtgtctgggt 3338
 agtactgctt gtttgtgtaa gcgccgttgg tgctcattga tgattccttt gaagtgtttg 3398
 gaggtcggct agtagtcggc cgtatgtgct tgctttttgc tcgtgatagc tcgccttggc 3458

tatgaggtcg gctaggtagg ttcccggggt gcctaggttg cgtaggtcta gcaaattccc 3518
 gtatgtggcc tgtgcgtgc gctggtggtg catacagtcg ttaagctggg cttttacgtc 3578
 tgcgatgcgg tggcggttag gcatgttggt gtgcttcttc caagtactca cgggcgggtt 3638
 ttgtgtatgc ctggcgtgat gcttctttga gctgttgag ttccgcttgg agtgccggta 3698
 gtccgtccgc gaactgcttg tggactcgt atttctcttg ttccctggcg atagcatttg 3758
 cgttgaattg cagggcgggt agttcgtcca cgcgtcgttt tgctgcgttg gtcatggttg 3818
 cgtgccattt gcggttggtg acgcgggggt caaggttgcg cacggctgct tcggctaggt 3878
 tgggtgctgc ttttttcagt gctcgggctt cccgttcctc gtccaacgag agcaccttg 3938
 gttgttggtc ttccgctagt ttttgcttct ccgctttgat gagttggtca acttcgtgtt 3998
 gggagaggtc gtttttcacg atgcgtcgaa tgtggtcgtt gtgggtgctg agttggtgtg 4058
 agaggtagtg gggttctggg atttcggcga gttggtcgag gttggtgtag tgcgggttgc 4118
 ggcttggttg gttgggttcg ctggggaggt cgatgtatcc ggttgagtct ccggcgtggt 4178
 tgaagtgaat taggcgttg tagccgtatt cctggttggg gaggtacgac agaatgagga 4238
 agtttggtgc ttctcctgca atgagtcgtg cgtgttcgta gttcgttact gggctcgtct 4298
 cggggagaat gttcttttgg gtcatggctt ctctttctgt tgctctgtaa gtccgtatgt 4358
 gggcatggga aagccccggc aacccttttg gtcaaccggg gctagatagt cgcttagaat 4418
 ggcttctagg ctgcgtctcg ggggtgtg 4447

<210> 6

<211> 427

<212> PRT

<213> Brevibacterium lactofermentum

<400> 6

Val	Asn	Thr	Ser	Lys	Glu	Pro	Gln	Val	Asn	Glu	Gly	Ser	Lys	Val	Thr
1				5					10					15	
Arg	Ala	Arg	Ala	Trp	Arg	Arg	Gln	Asn	Val	Met	Tyr	Lys	Ile	Thr	Asn
			20				25						30		
Ser	Lys	Ala	Leu	Ala	Gly	Cys	His	Arg	Trp	Arg	Arg	Asp	Glu	Ala	Val
		35				40					45				
Ala	Val	Ser	Trp	Ser	Ser	Asn	Gly	Ala	Ser	Gln	Phe	Glu	Gly	Leu	Gln
	50					55				60					
Asn	Ser	His	Ser	Arg	Trp	Gly	Ser	Pro	Leu	Ala	Glu	Leu	Glu	Val	Met
65				70				75					80		
Gly	Glu	Arg	Arg	Ile	Glu	Leu	Ala	Ile	Ala	Thr	Lys	Asn	His	Leu	Ala
			85					90					95		
Ala	Gly	Gly	Ala	Leu	Met	Met	Phe	Val	Gly	Thr	Val	Arg	His	Asn	Arg
		100						105					110		
Ser	Gln	Ser	Phe	Ala	Gln	Val	Glu	Ala	Gly	Ile	Lys	Thr	Ala	Tyr	Ser
		115					120					125			
Ser	Met	Val	Lys	Thr	Ser	Gln	Trp	Lys	Lys	Glu	Arg	Ala	Arg	Tyr	Gly

130	135	140
Val Glu His Thr Tyr Ser Asp Tyr Glu Val Thr Asp Ser Trp Ala Asn		
145	150	155
Gly Trp His Leu His Arg Asn Met Leu Leu Phe Leu Asp Arg Pro Leu		160
	165	170
Ser Asp Asp Glu Leu Lys Ala Phe Glu Asp Ser Met Phe Ser Arg Trp		175
	180	185
Ser Ala Gly Val Val Lys Ala Gly Met Asp Ala Pro Leu Arg Glu His		190
	195	200
Gly Val Lys Leu Asp Gln Val Ser Thr Trp Gly Gly Asp Ala Ala Lys		205
	210	215
Met Ala Thr Tyr Leu Ala Lys Gly Met Ser Gln Glu Leu Thr Gly Ser		220
225	230	235
Ala Thr Lys Thr Ala Ser Lys Gly Ser Tyr Thr Pro Phe Gln Met Leu		240
	245	250
Asp Met Leu Ala Asp Gln Ser Asp Ala Gly Glu Asp Met Asp Ala Val		255
	260	265
Leu Val Ala Arg Trp Arg Glu Tyr Glu Val Gly Ser Lys Asn Leu Arg		270
	275	280
Ser Ser Trp Ser Arg Gly Ala Lys Arg Ala Leu Gly Ile Asp Tyr Ile		285
	290	295
Asp Ala Asp Val Arg Arg Glu Met Glu Glu Glu Leu Tyr Lys Leu Ala		300
305	310	315
Gly Leu Glu Ala Pro Glu Arg Val Glu Ser Thr Arg Val Ala Val Ala		320
	325	330
Leu Val Lys Pro Asp Asp Trp Lys Leu Ile Gln Ser Asp Phe Ala Val		335
	340	345
Arg Gln Tyr Val Leu Asp Cys Val Asp Lys Ala Lys Asp Val Ala Ala		350
	355	360
Ala Gln Arg Val Ala Asn Glu Val Leu Ala Ser Leu Gly Val Asp Ser		365
	370	375
Thr Pro Cys Met Ile Val Met Asp Asp Val Asp Leu Asp Ala Val Leu		380
385	390	395
Pro Thr His Gly Asp Ala Thr Lys Arg Asp Leu Asn Ala Ala Val Phe		400
	405	410
Ala Gly Asn Glu Gln Thr Ile Leu Arg Thr His		415
	420	425

<210> 7

<211> 4447

<212> DNA

<213> *Brevibacterium lactofermentum*

<220>

<221> CDS

<222> (1318)..(2598)

<400> 7

```

aagcttgctt acgtctgatg ctttgaatcg gacggacttg ccgatcttgt atgcggtgat 60
ttttccctcg tttgccact ttttaatggt ggccgggggtg agagctacgc gggcggcgac 120
ctgctgcgct gtgatccaat attcggggtc gttcactggt tcccccttct gatttctggc 180
atagaagaac ccccgatgaac tgtgtgggtc cggggggttc tgatttttgc gagacttctc 240
gcgcaattcc ctagcttagg tgaaaacacc atgaaacact agggaaacac ccatgaaaca 300
cccattaggg cagtagggcg gcttcttcgt ctagggcttg catttgggcg gtgatctggt 360
ctttagcgtg tgaaagtgtg tcgtaggtgg cgtgctcaat gcaactgaac gtcacgtcat 420
ttaccgggtc acgggtggga aagagaacta gtgggttaga cattgttttc ctggttgcg 480
gtgggtggtg gcttttctag ccgctcggtg aacgcggcga tcatgaactc ttggaggttt 540
tcaccgttct gcgtgcctgc gcgcttcagt tcctcacgta gtgccaaagg aacgcgtgcg 600
gtgaccacga cgggcttagc ctttgcctgc gcttctagt cttcgatggt ggcttgtgcc 660
tgcgttgcgt gcgcctgtag tgccgttga gcttcttga gttgctgttc tagctgtgcc 720
ttggttgcca tgccttaaga ctctagtagc ttctctgcga tatgtcatgc gcgtgcgtag 780
caaacattgt cctgcaactc attcattatg tgcagtgcct ctgttactag tcgtacatac 840
tcatatttac ctagtctgca tgcagtgcct gcacatgcag tcatgtcgtg ctaatgtgta 900
aaacatgtac atgcagattg ctgggggtgc agggggcgga gccaccctgt ccatgcgggg 960
tgtggggctt gcccgccgg tacagacagt gagcaccggg gcacctagtc gcggataccc 1020
cccctaggta tcggacacgt aaccctccca tgcgatgca aatctttaac attgagtacg 1080
ggtaagctgg cagcatagc caagctaggc ggccaccaa caccactaaa aattaatagt 1140
tcctagacaa gacaaacccc cgtgcgagct accaactcat atgcacgggg gccacataac 1200
ccgaagggtt ttaattgac aaccatagca ctagctaaga caacgggcac aacatccgca 1260
caaactcgca ctgcgcaacc ccgcacaaca tcgggtctag gtaacactga aatagaa 1317
gtg aac acc tct aag gaa ccg cag gtc aat gag ggt tct aag gtc act 1365
Val Asn Thr Ser Lys Glu Pro Gln Val Asn Glu Gly Ser Lys Val Thr
      1              5              10              15
cgc gct agg gcg tgg cgt agg caa aac gtc atg tac aag atc acc aat 1413
Arg Ala Arg Ala Trp Arg Arg Gln Asn Val Met Tyr Lys Ile Thr Asn
      20              25              30
agt aag gct ctg gcg ggg tgc cat agg tgg cgc agg gac gaa gct gtt 1461
Ser Lys Ala Leu Ala Gly Cys His Arg Trp Arg Arg Asp Glu Ala Val
      35              40              45
gcg gtg tcc tgg tgc tct aac ggt gct tgc cag ttt gag ggt ctg caa 1509
Ala Val Ser Trp Ser Ser Asn Gly Ala Ser Gln Phe Glu Gly Leu Gln
      50              55              60

```

aac tct cac tct cgc tgg ggg tca tct ctg gct gaa ttg gaa gtc atg	1557
Asn Ser His Ser Arg Trp Gly Ser Ser Leu Ala Glu Leu Glu Val Met	
65 70 75 80	
ggc gaa cgc cgc att gag ctg gct att gct act aag aat cac ttg gcg	1605
Gly Glu Arg Arg Ile Glu Leu Ala Ile Ala Thr Lys Asn His Leu Ala	
85 90 95	
gcg ggt ggc gcg ctc atg atg ttt gtg ggc act gtt cga cac aac cgc	1653
Ala Gly Gly Ala Leu Met Met Phe Val Gly Thr Val Arg His Asn Arg	
100 105 110	
tca cag tca ttt gcg cag gtt gaa gcg ggt att aag act gcg tac tct	1701
Ser Gln Ser Phe Ala Gln Val Glu Ala Gly Ile Lys Thr Ala Tyr Ser	
115 120 125	
tcg atg gtg aaa aca tct cag tgg aag aaa gaa cgt gca cgg tac ggg	1749
Ser Met Val Lys Thr Ser Gln Trp Lys Lys Glu Arg Ala Arg Tyr Gly	
130 135 140	
gtg gag cac acc tat agt gac tat gag gtc aca gac tct tgg gcg aac	1797
Val Glu His Thr Tyr Ser Asp Tyr Glu Val Thr Asp Ser Trp Ala Asn	
145 150 155 160	
ggt tgg cac ttg cac cgc aac atg ctg ttg ttc ttg gat cgt cca ctg	1845
Gly Trp His Leu His Arg Asn Met Leu Leu Phe Leu Asp Arg Pro Leu	
165 170 175	
tct gac gat gaa ctc aag gca ttt gag gat tcc atg ttt tcc cgc tgg	1893
Ser Asp Asp Glu Leu Lys Ala Phe Glu Asp Ser Met Phe Ser Arg Trp	
180 185 190	
tct gct ggt gtg gtt aag gcc ggt atg gac gcg cca ctg cgt gag cac	1941
Ser Ala Gly Val Val Lys Ala Gly Met Asp Ala Pro Leu Arg Glu His	
195 200 205	
ggg gtc aaa ctt gat cag gtg tct acc tgg ggt gga gac gct gcg aaa	1989
Gly Val Lys Leu Asp Gln Val Ser Thr Trp Gly Gly Asp Ala Ala Lys	
210 215 220	
atg gca acc tac ctc gct aag ggc atg tct cag gaa ctg act ggc tcc	2037
Met Ala Thr Tyr Leu Ala Lys Gly Met Ser Gln Glu Leu Thr Gly Ser	
225 230 235 240	
gct act aaa acc gcg tct aaa ggg tcg tac acg ccg ttt cag atg ttg	2085
Ala Thr Lys Thr Ala Ser Lys Gly Ser Tyr Thr Pro Phe Gln Met Leu	
245 250 255	
gat atg ttg gcc gat caa agc gac gcc ggc gag gat atg gac gct gtt	2133
Asp Met Leu Ala Asp Gln Ser Asp Ala Gly Glu Asp Met Asp Ala Val	
260 265 270	
ttg gtg gct cgg tgg cgt gag tat gag gtt ggt tct aaa aac ctg cgt	2181
Leu Val Ala Arg Trp Arg Glu Tyr Glu Val Gly Ser Lys Asn Leu Arg	

275	280	285	
tgc tct tgg tca cgt ggg gct aag cgt gct ttg ggc att gat tac ata			2229
Ser Ser Trp Ser Arg Gly Ala Lys Arg Ala Leu Gly Ile Asp Tyr Ile			
290	295	300	
gac gct gat gta cgt cgt gaa atg gaa gaa gaa ctg tac aag ctc gcc			2277
Asp Ala Asp Val Arg Arg Glu Met Glu Glu Glu Leu Tyr Lys Leu Ala			
305	310	315	320
ggt ctg gaa gca ccg gaa cgg gtc gaa tca acc cgc gtt gct gtt gct			2325
Gly Leu Glu Ala Pro Glu Arg Val Glu Ser Thr Arg Val Ala Val Ala			
325	330	335	
ttg gtg aag ccc gat gat tgg aaa ctg att cag tct gat ttc gcg gtt			2373
Leu Val Lys Pro Asp Asp Trp Lys Leu Ile Gln Ser Asp Phe Ala Val			
340	345	350	
agg cag tac gtt cta gat tgc gtg gat aag gct aag gac gtg gcc gct			2421
Arg Gln Tyr Val Leu Asp Cys Val Asp Lys Ala Lys Asp Val Ala Ala			
355	360	365	
gcg caa cgt gtc gct aat gag gtg ctg gca agt ctg ggt gtg gat tcc			2469
Ala Gln Arg Val Ala Asn Glu Val Leu Ala Ser Leu Gly Val Asp Ser			
370	375	380	
acc ccg tgc atg atc gtt atg gat gat gtg gac ttg gac gcg gtt ctg			2517
Thr Pro Cys Met Ile Val Met Asp Asp Val Asp Leu Asp Ala Val Leu			
385	390	395	400
cct act cat ggg gac gct act aag cgt gat ctg aat gcg gcg gtg ttc			2565
Pro Thr His Gly Asp Ala Thr Lys Arg Asp Leu Asn Ala Ala Val Phe			
405	410	415	
gcg ggt aat gag cag act att ctt cgc acc cac taaaagcggc ataaaccccg			2618
Ala Gly Asn Glu Gln Thr Ile Leu Arg Thr His			
420	425		
ttcgatattt tgtgcgatga atttatggtc aatgtcgcgg gggcaaacta tgatgggtct			2678
tggtgttgac aatggctgat ttcacagga atggaactgt catgctgtta tgtgcctggc			2738
tcctaatacaa agctggggac aatgggttgc cccgttgatc tgatctagtt cggattggcg			2798
gggcttcact gtatctgggg gtggcatcgt gaatagattg cacaccgtag tgggcagtgt			2858
gcacaccata gtggcatga gtaataccta cgcgcgcgtg ggctagggt taacgcgcgt			2918
tttccgtgc tgcggggcat acgttagcgc atacgctttt ttctgtgaaa cctttttgtg			2978
ttgtgtttc gtgttggtt cttttctgtt ggccgggcaa cttaacgcct gcgggggtgg			3038
ttgttgacgt taacgggggt agtttttatt cccctagtgg tttttcagta cgacaatcga			3098
gaaagacctg tttcagccag ttcgggtcat gtctgtcggg atggccacgt gcatagcgac			3158
cagttttcga gttcactggg atttttggtg catcaaacia gatgtaggac aatgcggttt			3218
ctaggtctac tttttgcttt atgcctgaca agccccgtgg gtattcagcg attgattcca			3278
aggcggttc ccagtcctgt tttgtgaagg actggcttag ttctaggtct gtgtctgggt			3338
agtactgctt gtttgtgtaa gcgccgttgg tgctcattga tgattccttt gaagtgtttg			3398

gagttcggct agtagtgcgg cgtatggtgc tgctttttgc tcgtgatagc tcgccttgge 3458
 tatgaggtcg gctaggtagg ttccgggggt gcctaggttg cgtaggtcta gcaaattccc 3518
 gtatgtggcc tgtgcgctgc gctggtggtg catacagtcg ttaagctggg cttttacgtc 3578
 tgcgatgcgg tggcggttag gcatgttggt gtgcttcttc caagtactca cgggcggggt 3638
 ttgtgtatgc ctggcgtgat gcttctttga gctgttgagg ttccgcttg agtgcgggta 3698
 gttcgccgc gaactgcttg tggactcgt atttctcttg ttccctggcg atagcatttg 3758
 cgttgaattg cagggcgggt agttcgtcca cgcgtcgtt tgctgcgttg gtcatggtg 3818
 cgtgccattt gcggttggtg acgcgggggt caaggttgcg cacggctgct tcggctaggt 3878
 tggtagctgc ttttttcagt gctcgggctt cccgttctc gtccaacgag agcacctttg 3938
 gttgttggtc ttggcctagt ttttgcttct ccgctttgat gagttggtca acttcgtgtt 3998
 gggagaggtc gtttttcacg atgcgtcgaa tgtggtcgtt gtgggtgctg agttggtgtg 4058
 agaggtagtg gggttctggg atttcggcga gttggtcgag gttggtgtag tgcgggttgc 4118
 ggcctggttg gttgggttcg ctggggaggt cgatgtatcc ggttgagtct ccggcggttg 4178
 tgaagtgaat taggcgttg tagccgtatt cctggttggg gaggtacgac agaattagga 4238
 agtttggtgc ttctctgca atgagtcgtg cgtgttcgta gttcggtact gggctgtgct 4298
 cggggagaat gttcttttg gtcatggctt ctctttctgt tgctctgtaa gtccgtatgt 4358
 gggcatggga aagccccggc aaccctttg gtcaaccggg gctagatagt cgcttagaat 4418
 ggcttctagg ctgcgtctcg ggggtggtc 4447

<210> 8

<211> 427

<212> PRT

<213> *Brevibacterium lactofermentum*

<400> 8

Val	Asn	Thr	Ser	Lys	Glu	Pro	Gln	Val	Asn	Glu	Gly	Ser	Lys	Val	Thr
1				5				10						15	
Arg	Ala	Arg	Ala	Trp	Arg	Arg	Gln	Asn	Val	Met	Tyr	Lys	Ile	Thr	Asn
			20				25						30		
Ser	Lys	Ala	Leu	Ala	Gly	Cys	His	Arg	Trp	Arg	Arg	Asp	Glu	Ala	Val
		35				40					45				
Ala	Val	Ser	Trp	Ser	Ser	Asn	Gly	Ala	Ser	Gln	Phe	Glu	Gly	Leu	Gln
	50					55				60					
Asn	Ser	His	Ser	Arg	Trp	Gly	Ser	Ser	Leu	Ala	Glu	Leu	Glu	Val	Met
	65			70					75					80	
Gly	Glu	Arg	Arg	Ile	Glu	Leu	Ala	Ile	Ala	Thr	Lys	Asn	His	Leu	Ala
			85					90					95		
Ala	Gly	Gly	Ala	Leu	Met	Met	Phe	Val	Gly	Thr	Val	Arg	His	Asn	Arg
		100					105						110		
Ser	Gln	Ser	Phe	Ala	Gln	Val	Glu	Ala	Gly	Ile	Lys	Thr	Ala	Tyr	Ser
	115						120						125		

Ser Met Val Lys Thr Ser Gln Trp Lys Lys Glu Arg Ala Arg Tyr Gly
 130 135 140
 Val Glu His Thr Tyr Ser Asp Tyr Glu Val Thr Asp Ser Trp Ala Asn
 145 150 155 160
 Gly Trp His Leu His Arg Asn Met Leu Leu Phe Leu Asp Arg Pro Leu
 165 170 175
 Ser Asp Asp Glu Leu Lys Ala Phe Glu Asp Ser Met Phe Ser Arg Trp
 180 185 190
 Ser Ala Gly Val Val Lys Ala Gly Met Asp Ala Pro Leu Arg Glu His
 195 200 205
 Gly Val Lys Leu Asp Gln Val Ser Thr Trp Gly Gly Asp Ala Ala Lys
 210 215 220
 Met Ala Thr Tyr Leu Ala Lys Gly Met Ser Gln Glu Leu Thr Gly Ser
 225 230 235 240
 Ala Thr Lys Thr Ala Ser Lys Gly Ser Tyr Thr Pro Phe Gln Met Leu
 245 250 255
 Asp Met Leu Ala Asp Gln Ser Asp Ala Gly Glu Asp Met Asp Ala Val
 260 265 270
 Leu Val Ala Arg Trp Arg Glu Tyr Glu Val Gly Ser Lys Asn Leu Arg
 275 280 285
 Ser Ser Trp Ser Arg Gly Ala Lys Arg Ala Leu Gly Ile Asp Tyr Ile
 290 295 300
 Asp Ala Asp Val Arg Arg Glu Met Glu Glu Glu Leu Tyr Lys Leu Ala
 305 310 315 320
 Gly Leu Glu Ala Pro Glu Arg Val Glu Ser Thr Arg Val Ala Val Ala
 325 330 335
 Leu Val Lys Pro Asp Asp Trp Lys Leu Ile Gln Ser Asp Phe Ala Val
 340 345 350
 Arg Gln Tyr Val Leu Asp Cys Val Asp Lys Ala Lys Asp Val Ala Ala
 355 360 365
 Ala Gln Arg Val Ala Asn Glu Val Leu Ala Ser Leu Gly Val Asp Ser
 370 375 380
 Thr Pro Cys Met Ile Val Met Asp Asp Val Asp Leu Asp Ala Val Leu
 385 390 395 400
 Pro Thr His Gly Asp Ala Thr Lys Arg Asp Leu Asn Ala Ala Val Phe
 405 410 415
 Ala Gly Asn Glu Gln Thr Ile Leu Arg Thr His
 420 425

<210> 9

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for
introducing mutation to pAM330

<400> 9

aaacccgggc tacgtctgat gctttgaatc

30

<210> 10

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for
introducing mutation to pAM330

<400> 10

tttgatcccc cgtaaagtc aacaacc

27

<210> 11

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for
introducing mutation to pAM330

<400> 11

ttttcccggg agcttgccac accccgag

28

<210> 12

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for
introducing mutation to pAM330

<400> 12
gggggtcatc tctggctgaa ttgg 24

<210> 13

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for
introducing mutation to pAM330

<400> 13
gaggttttca ccgttctgca tgcc 24

<210> 14

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for
introducing mutation to pAM330

<400> 14
aactcaccgc cctgcaattc aac 23

<210> 15

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for PCR

<400> 15
gcctaccgcg gcaaagaagt ggcag 25

<210> 16

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for PCR

<400> 16

gccttgaact aggggcgctt taagt

25

<210> 17

<211> 4235

<212> DNA

<213> *Brevibacterium flavum*

<220>

<221> CDS

<222> (1852)..(2364)

<400> 17

```

aaacccgggt tttcttctgc aactcgggcg ccgaagcaaa cgagctgctt ttcaagattg 60
cacgcttgac tggctgttcc cggattctgg ctgcagttca tggtttccac ggccgcacca 120
tgggttcctt cgcgctgact ggccagccag acaagcgtga agcgttcctg ccaatgccaa 180
gcggtgtgga gttctacctt tacggcgaca ccgattactt gcgcaaaatg gtagaaacca 240
acccaacgga tgtggctgct atcttcctcg agccaatcca gggtgaaacg ggcgttggtc 300
cagcacctga aggattcctc aaggcagtgc gcgagctgtg cgatgagtac ggcattctga 360
tgatcaccca tgaagtccag actggcgttg gccgtaccgg cgatttcttt gcacatcagc 420
acgatggcgt tgttcccgat gtggtgacca tggccaaggg acttggcggc ggtcttccca 480
tcggtgcttg tttggccact ggccgtgcag ctgaattgat gacccaggc aagcacggca 540
ccactttcgg tggcaacca gttgcttggt cagctgccaa ggcagtgtg tctgttgctg 600
atgacgcttt ctgcgcagaa gttaccgca agggcgagct gttcaaggta cttcttgcca 660
aggttgacgg cgtttagtag gtccgtggca ggggcttgat gttgggcgtg gtgctggagc 720
gcgacgtcgc aaagcaagct gttcttgatg gttttaagca cggcgttatt ttgaatgcac 780
cggcggacaa cattatcgtt ttgacccgcg cgctggtgat caccgacgaa gaaatcgagc 840
acgcagtcaa ggctattgcc gagacaatcg cataaaggac ttaaacttat gacttcacaa 900
ccacaggttc gccatttctt ggctgatgat gatctacccc ctgcagagca ggcagaggtt 960
ttgaccctag ccgcaaagct caaggcagcg ccgttttcgg agcgtccact cgagggacca 1020
aagtcggttg cagttctttt tgataagact tcaactcgta ctgccttctc cttcgacgcg 1080
ggcatcgctc atttgggttg acatgccatc gtctgggatt ccggcagctc acagatgggt 1140
aagggcgaga ccctgcagga caccgcagct gtattgtccc gctacgtgga agcaattgtg 1200
tggcgcacct acgcacacag caatttccac gccatggcgg agacgtccac tgtgccgctg 1260
gtgaactcct tgtccgatga tctgcacca tgccagattc tggctgatct gcagaccate 1320

```

gtggaaaacc tcagccctga agaaggccca gcaggcctta agggtaagaa ggctgtgtac 1380
 ctgggcatg gcgacaacaa catggccaac tcctacatga ttggctttgc caccgcgggc 1440
 atggatatatt ccatcatcgc tcctgaaggg ttccagcctc gtgcggaatt cgtggagcgc 1500
 gcggaaaagc gtggccagga aaccggcgcg aaggttggtg tcaccgacag cctcgacgag 1560
 gttgccggcg ccgatgttgt catcaccgat acctgggtat ccatgggtat ggaaaacgac 1620
 ggcatcgatc gcaccacacc ttctgttctt taccaggtca acgatgaggt catggcgaaa 1680
 gctaacgacg gcgccatctt cctgcactgc ctctctgcct accgcggcaa agaagtggca 1740
 gcctccgtga ttgatggacc agcgtccaaa gttttcgatg aagcagaaaa ccgcctccac 1800
 gctcagaaag cactgctggt gtggctgctg gccaccagc cgaggtaga c atg tct 1857

Met Ser

1

ctt ggc tca acc cgc tca aca ccg gaa aac tta aat ccc gtg act cgc 1905
 Leu Gly Ser Thr Pro Ser Thr Pro Glu Asn Leu Asn Pro Val Thr Arg

5

10

15

act gca cgc caa gct ctc att ttg cag att ttg gac aaa caa aaa gtc 1953
 Thr Ala Arg Gln Ala Leu Ile Leu Gln Ile Leu Asp Lys Gln Lys Val

20

25

30

acc agc cag gta caa ctg tct gaa ttg ctg ctg gat gaa ggc atc gat 2001
 Thr Ser Gln Val Gln Leu Ser Glu Leu Leu Leu Asp Glu Gly Ile Asp

35

40

45

50

atc acc cag gcc acc ttg tcc cgg gat ctc gat gaa ctc ggt gca cgc 2049
 Ile Thr Gln Ala Thr Leu Ser Arg Asp Leu Asp Glu Leu Gly Ala Arg

55

60

65

aag gtt cgc ccc gat ggg gga cgc gcc tac tac gcg gtc ggc cca gta 2097
 Lys Val Arg Pro Asp Gly Gly Arg Ala Tyr Tyr Ala Val Gly Pro Val

70

75

80

gat agc atc gcc cgc gaa gat ctc cgg ggt ccg tcg gag aag ctg cgc 2145
 Asp Ser Ile Ala Arg Glu Asp Leu Arg Gly Pro Ser Glu Lys Leu Arg

85

90

95

cgc atg ctt gat gaa ctg ctg gtt tct aca gat cat tcc ggc aac atc 2193
 Arg Met Leu Asp Glu Leu Leu Val Ser Thr Asp His Ser Gly Asn Ile

100

105

110

gcg atg ctg cgc acc ccg ccg gga gct gcc cag tac ctg gca agt ttc 2241
 Ala Met Leu Arg Thr Pro Pro Gly Ala Ala Gln Tyr Leu Ala Ser Phe

115

120

125

130

atc gat agg gtg ggg ctg aaa gaa gtc gtt ggc acc atc gct ggc gat 2289
 Ile Asp Arg Val Gly Leu Lys Glu Val Val Gly Thr Ile Ala Gly Asp

135

140

145

gac acc gtt ttt gtt ctc gcc cgt gat ccg ctc aca ggt aaa gaa cta 2337
 Asp Thr Val Phe Val Leu Ala Arg Asp Pro Leu Thr Gly Lys Glu Leu

150

155

160

ggt gaa tta ctc agc ggg cgc acc act taaagcgccc ctagttcaag 2384
 Gly Glu Leu Leu Ser Gly Arg Thr Thr

165

170

gcttgtaaat cgcttgtaaa tgcaggcagg taaggtataa cccgagtgtt ttttcgagga 2444
 ataccaaccc tttcaacaca ataattttct ttaaacaacc ttgctgtcca ccacggctgg 2504
 caaggaactt aaaatgaagg agcacacctc atgactaacc gcatcgttct tgcatactcc 2564
 ggcggtcttg acaccactgt ggcaattcca tacctgaaga agatgattga tggtaagtc 2624
 atcgcagttt ctctcgacct gggccagggt ggagagaaca tggacaacgt tcgccagcgt 2684
 gcattggatg ccggtgcagc tgagtccatc gttgttgatg caaaggatga gttcgtgag 2744
 gagtactgcc tgccaacat caaggcaaac ggcattgtaca tgaagcagta cccactggtt 2804
 tctgcaatct cccgccact gatcgtcaag cacctcgttg aggctggcaa gcagttcaac 2864
 ggtacccacg ttgcacacgg ctgcactggt aagggaacg accaggttcg tttcgaggtc 2924
 ggcttcatgg acaccgatcc aaacctggag atcattgcac ctgctcgtga cttcgcatgg 2984
 acccgcgaca aggctatcgc cttcgccgag gagaacaacg ttccaatoga gcagtcogtg 3044
 aagtccecat tctccatcga ccagaacgtc tggggccgag ctattgagac cggttacctg 3104
 gaagatctgt ggaatgctcc aaccaaggac atctacgat acaccgagga tccagctctg 3164
 ggtaacgctc cagatgaggt catcatctcc ttcgagggtg gcaagccagt ctccatgat 3224
 ggccgtccag tctccgtact gcaggctatt gaagagctga accgtcgtgc aggcgcacag 3284
 ggcgttgccc gccttgacat ggttgaggac cgtctcgtgg gcatcaagtc ccgcgaaatc 3344
 tacgaagcac caggcgcaat cgcactgatt aaggctcacg aggttttga agatgtcacc 3404
 atcgagcgcg aactggctcg ctacaagcgt ggcgttgacg cacgttgggc tgaggaaagta 3464
 tacgacggcc tgtggttcgg acctctgaag cgctccctgg acgcgttcac tgattccacc 3524
 caggagcacg tcaccggcga tatccgcgat gttctgcacg caggttccat caccatcaat 3584
 ggtcgtcgtt ccagccactc cctgtacgac ttcaacctgg ctacctacga caccggcgac 3644
 accttcgacc agacctggc taagggtttt gtccagctgc acggtctgtc ctccaagatc 3704
 gctaacaagc gcgatcgca agctggcaac aactaagcca ctttttcaag catccagact 3764
 agaacttcaa gtatttagaa agtagaagaa caccacatgg aacagcacgg aaccaatgaa 3824
 ggtgcgctgt ggggcggcgg cttctccggt ggacctccg aggccatgtt cgcttgagt 3884
 gtctccactc atttcgactg ggttttgccc ctttatgatg tgttgccctc caaggcacac 3944
 gccaaagttt tgcaccaagc agagctactt tctgatgaag atctagccac catgctggct 4004
 ggtcttgatc agctgggcaa ggatgtcgcc gacggaacct tcggtccgct gccttctgat 4064
 gaggatgtgc acggcgcgat ggaacgcggt ctgattgacc gcgttggtcc tgagggtggc 4124
 ggccgtctgc gcgtggtcg ttcccgcaac gaccaggtgg caacctgtt ccgcatgttg 4184
 gtccgcgacg cagtgcgca catcgcgctg ggaacaaccg agcttgcga c 4235

<210> 18

<211> 171

<212> PRT

<213> Brevibacterium flavum

<400> 18

Met Ser Leu Gly Ser Thr Pro Ser Thr Pro Glu Asn Leu Asn Pro Val
 1 5 10 15
 Thr Arg Thr Ala Arg Gln Ala Leu Ile Leu Gln Ile Leu Asp Lys Gln
 20 25 30
 Lys Val Thr Ser Gln Val Gln Leu Ser Glu Leu Leu Leu Asp Glu Gly
 35 40 45
 Ile Asp Ile Thr Gln Ala Thr Leu Ser Arg Asp Leu Asp Glu Leu Gly
 50 55 60
 Ala Arg Lys Val Arg Pro Asp Gly Gly Arg Ala Tyr Tyr Ala Val Gly
 65 70 75 80
 Pro Val Asp Ser Ile Ala Arg Glu Asp Leu Arg Gly Pro Ser Glu Lys
 85 90 95
 Leu Arg Arg Met Leu Asp Glu Leu Leu Val Ser Thr Asp His Ser Gly
 100 105 110
 Asn Ile Ala Met Leu Arg Thr Pro Pro Gly Ala Ala Gln Tyr Leu Ala
 115 120 125
 Ser Phe Ile Asp Arg Val Gly Leu Lys Glu Val Val Gly Thr Ile Ala
 130 135 140
 Gly Asp Asp Thr Val Phe Val Leu Ala Arg Asp Pro Leu Thr Gly Lys
 145 150 155 160
 Glu Leu Gly Glu Leu Leu Ser Gly Arg Thr Thr
 165 170

<210> 19

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for PCR

<400> 19

cccgggtttt cttctgcaac tcggg

25

<210> 20

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer for PCR

<400> 20
gtcgacaagc tcggttggtc ccagc 25

<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer for PCR

<400> 21
cccctagttc aaggcttggtt aatc 24

<210> 22
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer for PCR

<400> 22
gtcttacctc ggctggttgg ccagc 25